Auna SA reported consolidated revenue of S/1,117.0 million for the third quarter of 2025, representing a 1.0% increase at constant exchange rates and a 1.0% decrease year-over-year on a reported basis. Adjusted EBITDA declined by 5.0% at constant exchange rates, or 7.0% year-over-year on a reported basis, to S/232.0 million, with an adjusted EBITDA margin of 20.8%, down from 22.1% in the third quarter of 2024. Net finance costs were S/72.0 million, compared to S/103.0 million a year earlier, with a positive FX impact of S/40.0 million. Net income was S/53.0 million, or S/0.65 per share, while adjusted net income was S/58.0 million, or S/0.71 per share, both lower than the previous year. The leverage ratio remained at 3.6x. In Mexico, surgeries and oncology services increased for the second consecutive quarter, and the oncology medical loss ratio decreased to 49.3%.